← Leaderboards
Felipe Andrade
Johns Hopkins University
$7,256,287
Attributed
$7,481,443
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,481,443 · 11
By mechanism
R01$4,112,395 · 2
R21$3,273,809 · 8
P30$95,239 · 1
Top collaborators
- Maximilian Ferdinand Konig2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Mei Wan$12,070,256
- Mary E McCaul$21,975,059
- John Riley Lever$1,109,181
- Neal S Fedarko$7,117,033
- Erika Darrah$1,058,778
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisAntigensAutoantibodiesAutoantigensProteinsCellsInsightCohortInflammationAntibodiesMediatingPathway InteractionsProductionNeutrophilPathogenicityEtiologyTissuesPrevalenceLinkGenesAutoimmune DiseasesAutoimmunityImmune ResponseSystemic Lupus Erythematosus
Grant awards (28)
The role of cytotoxic T cells in rheumatoid arthritis pathogenesis$517,284
R01 · FY2025 · AR · contact PI
Izumo1 in remission in SLE$198,547
R21 · FY2025 · AI · contact PI
The antigenic origin of anti-dsDNA antibodies in SLE$198,547
R21 · FY2025 · AI · contact PI
Insights into the origin of ACPAs in RA$187,938
R21 · FY2025 · AI · contact PI
The role of cytotoxic T cells in rheumatoid arthritis pathogenesis$571,495
R01 · FY2024 · AR · contact PI
Izumo1 in remission in SLE$245,625
R21 · FY2024 · AI · contact PI
The antigenic origin of anti-dsDNA antibodies in SLE$245,625
R21 · FY2024 · AI · contact PI
Precision immunotherapies targeting the 9G4 idiotype in lupus erythematosus$204,688
R21 · FY2024 · AI
LINE1-ORF0 in SLE pathogenesis$204,688
R21 · FY2024 · AI · contact PI
The role of cytotoxic T cells in rheumatoid arthritis pathogenesis$586,363
R01 · FY2023 · AR · contact PI
LINE1-ORF0 in SLE pathogenesis$245,625
R21 · FY2023 · AI · contact PI
Precision immunotherapies targeting the 9G4 idiotype in lupus erythematosus$245,625
R21 · FY2023 · AI
Transcription factor A mitochondria in SLE pathogenesis$204,688
R21 · FY2023 · AI · contact PI
The role of cytotoxic T cells in rheumatoid arthritis pathogenesis$593,736
R01 · FY2022 · AR · contact PI
Transcription factor A mitochondria in SLE pathogenesis$245,625
R21 · FY2022 · AI · contact PI
Peptidylarginine deiminase type 6 in rheumatoid arthritis pathogenesis$396,275
R21 · FY2021 · AR · contact PI
Autoimmunity to LINE-1-encoded antigens in SLE pathogenesis$204,688
R21 · FY2021 · AI · contact PI
The role of complement citrullination in RA pathogenesis$359,865
R01 · FY2020 · AR · contact PI
Autoimmunity to LINE-1-encoded antigens in SLE pathogenesis$245,625
R21 · FY2020 · AI · contact PI
The role of complement citrullination in RA pathogenesis$366,673
R01 · FY2019 · AR · contact PI
The role of complement citrullination in RA pathogenesis$374,787
R01 · FY2018 · AR · contact PI
The role of complement citrullination in RA pathogenesis$364,628
R01 · FY2017 · AR · contact PI
The role of complement citrullination in RA pathogenesis$377,564
R01 · FY2016 · AR · contact PI
Granzyme B Genotypes in Scleroderma$11,224
P30 · FY2010 · AR · contact PI
Granzyme B Genotypes in Scleroderma$11,196
P30 · FY2009 · AR · contact PI
Granzyme B Genotypes in Scleroderma$11,610
P30 · FY2008 · AR · contact PI
Granzyme B Genotypes in Scleroderma$30,942
P30 · FY2007 · AR · contact PI
Granzyme B Genotypes in Scleroderma$30,267
P30 · FY2006 · AR · contact PI